Essential thrombocythemia: nutritional management in weight loss and malnutrition
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 47 (93) , 93
Abstract
Essential thrombocythemia is the category of myeloproliferative syndromes, generally characterized by a group of clonal stem cell diseases that present a disturbance in the growth of one or more sets of hematopoietic cells. All long clinical treatment, patients may experience gastrointestinal disorders and other metabolic processes that can lead to weight loss and malnutrition. Cytokine is involved in the control of appetite, digestive and metabolic processes in the body, it can be assumed that increased stimulation could impair the control of these processes leading to loss of body mass. Effective and systematic nutritional intervention is required to ensure patient compliance with treatment and improved nutritional status.Keywords
This publication has 6 references indexed in Scilit:
- Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasmsJournal of Thrombosis and Thrombolysis, 2020
- The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig DeepClinical Medicine Insights: Blood Disorders, 2020
- Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE RegistryBlood, 2018
- Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European UnionEuropean Journal of Haematology, 2014
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of ThrombosisNew England Journal of Medicine, 1995